GVK Biosciences has successfully completed in-silico based alternative indications of shelved compounds for Takeda Pharmaceutical Company using GVK BIO’s proprietary Drug Repurposing Platform. Taking the project to the next level, GVK BIO and Takeda have jointly agreed to evaluate the pre-clinical proof-of-concept for certain indications of selected therapeutic compounds to develop novel indications for the previously failed compounds.
Having worked for over a decade with global majors in the pharmaceutical industry, GVK BIO has leveraged its experience and expertise in drug discovery and has developed a unique Drug Repurposing Platform called GRIP (GVK BIO Repurposing Integrated Platform). GRIP is a combination of proprietary Repurposing Database, eight different repurposing algorithms, analytics tools and visualisation engine.
The re-purposing database consists of over 45 databases which enable the relationship between drug-target-disease. Drug re-purposing algorithms allow for unbiased interpretation of the input data to predict alternative indications. GVK BIO’s value proposition in drug re-purposing is that it offers in-silico analysis as well as pre-clinical support to execute projects and establish proof of concept.
Nandu Gattu, Vice President – Drug Repurposing, GVK BIO said, “GVK BIO is well known for its rich and extensive biological, chemical and clinical databases. A marriage between computational algorithms, analytical capabilities and our custom curated databases along with proven drug discovery experience enables us to develop a multi-pronged approach resulting in higher success rates.”
Sreeni Devidas, Vice President Business Development, GVK BIO said, “GVK BIO has leveraged its expertise in Informatics to successfully build it Drug Repositioning Platform. The success with Takeda illustrates the value add that this approach brings to enhance the pipeline of our customers and collaborators.”
EP News Bureau – Mumbai
